To include your compound in the COVID-19 Resource Center, submit it here.
MedImmune (MEDI) held up well last week after lowering its 2003 revenue guidance for FluMist. But investors already had come to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury